KR20160031247A - Composition for improving senile disorder and functional foods comprising same - Google Patents
Composition for improving senile disorder and functional foods comprising same Download PDFInfo
- Publication number
- KR20160031247A KR20160031247A KR1020140121034A KR20140121034A KR20160031247A KR 20160031247 A KR20160031247 A KR 20160031247A KR 1020140121034 A KR1020140121034 A KR 1020140121034A KR 20140121034 A KR20140121034 A KR 20140121034A KR 20160031247 A KR20160031247 A KR 20160031247A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- composition
- parts
- present
- zeaxanthin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
Abstract
The present invention relates to a composition for improving senile diseases and a functional food containing the same, and more particularly, to a composition and a functional food for improving senile diseases such as gum disease and visual acuity.
The composition of the present invention comprises 100 parts by weight of zeaxanthin; 50 parts by weight to 3,000 parts by weight of lutein; And 20 to 2,000 parts by weight of beta-sitosterol.
Description
The present invention relates to a composition for improving senile diseases and a functional food containing the same, and more particularly, to a composition and a functional food for improving senile diseases such as gum disease and visual acuity.
As humans aged, aging diseases rapidly appear and many efforts are being made to overcome them. Many of the geriatric diseases are associated with decreased visual acuity and gum deterioration, and medicines and health functional foods are being developed to improve them.
In general, lutein-containing compositions for suppressing visual deterioration and improving visual acuity are sold as health foods. In addition, pharmaceuticals that are corn extracts are sold to suppress gum deterioration. The main components of corn extract are beta-sitosterol, .
However, the above-mentioned geriatric diseases often require simultaneous treatment or simultaneous prevention or inhibition. However, there is a problem that the gums are worsened due to the deterioration of the gums and the drugs are sold as medicines or health foods have.
Therefore, it is necessary to combine the active ingredients to improve or prevent symptoms of the disease at low cost at the same time.
A problem to be solved by the present invention is to provide a composition capable of inhibiting or preventing an aging disease such as gum deterioration or visual loss.
Another object to be solved by the present invention is to provide a functional food comprising the composition.
According to an aspect of the present invention,
100 parts by weight of zeaxanthin;
50 parts by weight to 3,000 parts by weight of lutein; And
And 20 to 2,000 parts by weight of beta-sitosterol.
According to another aspect of the present invention,
And a functional food comprising the composition.
The composition for improving the geriatric diseases according to the present invention is a composition for improving the geriatric diseases which are inevitably accompanied by the progress of aging, such as gum deterioration or visual loss, combined with lutein and zeaxanthin as beta-sitosterol It is possible to prevent or suppress the symptoms in a complex manner at a low cost.
The terms and words used in the present specification and claims should not be construed as limited to ordinary or dictionary meanings and the inventor can properly define the concept of the term to describe its invention in the best possible way And should be construed in accordance with the principles and meanings and concepts consistent with the technical idea of the present invention.
Hereinafter, the present invention will be described in detail.
The composition for improving the geriatric disease according to the present invention comprises
100 parts by weight of zeaxanthin; 50 parts by weight to 3,000 parts by weight of lutein; And 20 to 2,000 parts by weight of beta-sitosterol.
Lutein, a component of the composition, is present in green leafy vegetables such as Spinach and Kale and lutein and zeaxanthin are found in Nasturtium, Spinach, googi berry, Kale It is used as a food additive as a food dye containing dandelion, broccoli, kiwi fruit, corn, egg yolks and the like It is known to have antioxidant properties.
In addition, these ingredients are essential nutrients for healthy eyes because they are a component of the macular composition in the retina center of the eye. Therefore, lutein and zeaxanthin play a role in reducing macular degeneration. However, these ingredients are not synthesized in the human body, so they need to be absorbed through food. It is known that the recommended daily dose is about 6 ~ 10mg of lutein and 2mg of zeaxanthin.
Beta-sitosterol, a component of the composition, is a generally known substance, and is a vitamin D precursor or a kind of provitamin D, which is known to have a wound healing effect in response to inflammation. It is contained in the corn, soybean, vegetable oil, seed, vegetable oil and the like and corresponds to the essential components of the plant. The beta-sitosterol is a phytosterol and has a structure similar to cholesterol. In the method of producing beta-sitosterol, US Pat. No. 2,835,682 extracts a sterol-containing substance and then a basic alcohol solution (US Pat. No. 2,866,797) discloses a method of crystallizing an unsaponifiable substance obtained from vegetable oils, tall oil, sugar cone oil, The process is disclosed in US Pat. No. 3,692,211, which discloses a process in which water, alcohol and a mixture of hydrocarbons are used in a toll passage. Discloses a process for crystallization after saponification after extraction, which documents are incorporated herein by reference.
In addition, U.S. Patent No. 4,265,824 discloses a process for preparing crude β-itosterol obtained from a plant by firstly purifying isopropanol using a solvent in which hydrogen chloride gas is injected into chloroform, To purify beta-sitosterol at a purity of 90% or more. Particularly, a technique of using toluene or ethanol instead of chloroform is also disclosed. Abstacts vol 81 (1974) 51409 discloses purification from crude phytosterol, and U.S. Patent No. 4,044,031 discloses extraction and purification methods, which are incorporated herein by reference.
The present invention provides a composition for improving the geriatric disease comprising the β-sitosterol and the lutein and zeaxanthin essentially including the combination of β-sitosterol and zeaxanthin for preventing or suppressing gum deterioration and visual deterioration.
According to one embodiment, the lutein may be used in an amount of about 50 parts by weight to about 3,000 parts by weight based on 100 parts by weight of zeaxanthin. In such a content range, it is possible to provide sufficient effects related to visual improvement.
According to one embodiment, the beta-sitosterol may be used in an amount of 20 to 2,000 parts by weight based on 100 parts by weight of the zeaxanthin. Such a thing? It is possible to sufficiently prevent and / or inhibit deterioration of gums in addition to the above-mentioned visual improvement effect.
According to one embodiment, the composition for improving geriatric diseases of the present invention may contain 1 to 10 mg of zeaxanthin, 5 to 30 mg of lutein, and 2 to 20 mg of beta-sitosterol on a daily basis on an adult basis.
According to one embodiment, the composition for improving senile diseases may further comprise one or two kinds of vitamin C and vitamin E to facilitate absorption of zeaxanthin. For example, From 100 parts by weight to 40,000 parts by weight of vitamin C and / or from 50 parts by weight to 3,000 parts by weight of vitamin E. In this range, the absorption rate of zeaxanthin can be sufficiently improved.
According to one embodiment, the composition for improving geriatric diseases of the present invention may contain 1 to 10 mg of zeaxanthin, 5 to 30 mg of lutein, 2 to 20 mg of beta-sitosterol and 10 to 400 mg of vitamin C on a daily basis on an adult basis.
According to one embodiment, the composition for improving geriatric diseases of the present invention may contain 1 to 10 mg of zeaxanthin, 5 to 30 mg of lutein, 2 to 20 mg of beta-sitosterol and 5 to 30 mg of vitamin E on an adult basis per day.
According to one embodiment, the composition for improving geriatric diseases of the present invention comprises 1 to 10 mg of zeaxanthin, 5 to 30 mg of lutein, 2 to 20 mg of beta-sitosterol, 10 to 400 mg of vitamin C and 5 to 30 mg of vitamin E per adult on a daily basis can do.
According to one embodiment, zeaxanthin and lutetin among the constituents of the composition are natural extracts, and extracts containing 20% or more of the active ingredient may be used. The beta-sitosterol and vitamin E (tocopherol) Can be used.
The composition according to the present invention, and capsules, formulations or tablets comprising it, are prepared in a manner known per se, for example by conventional mixing, granulating, coating, dissolving or lyophilizing processes.
The composition may be sterilized, for example, in a batch-wise, if appropriate, ingredient-wise manner and / or may contain excipients such as stabilizers, colorants, firming agents, wetting agents and / Solubilizers, salts for controlling osmotic pressure and / or buffers, and are prepared in a manner known per se, for example by conventional dissolution and freeze-drying methods. The solution or suspension may contain a thickening agent, typically sodium carboxymethylcellulose, carboxymethylcellulose, dextran, polyvinylpyrrolidone or gelatin, or also a solubilizing agent such as Tween 80 (polyoxyethylene (20) sor Non-carbon mono-oleate; Trademarks of ICI Americas, Inc "). ≪ / RTI >
The composition according to the present invention may be of various formulations, oral or parenteral. In the case of formulation, it may be prepared using diluents or excipients such as fillers, extenders, binders, humectants, disintegrants, surfactants and the like which are generally used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules, and the like, which may contain one or more excipients such as starch, calcium carbonate, sucrose or lactose lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate, talc, and the like may also be used.
Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like.
The composition of the present invention may contain, as an auxiliary component, vitamin B, beta-carotene, minerals containing compounds such as Ca, Mg and Zn, phospholipids such as lecithin or compounds such as maltol and amino acid as auxiliary components.
In addition to the above components, natural additives such as natural flavors such as plum, lemon flavor, pineapple flavor or herb flavor, natural fruit juice, natural pigments such as chlorophyllin and flavonoid and sweeteners such as fructose, Honey, sugar alcohol, sugar and the like may be mixed with an acid agent such as citric acid or sodium citrate.
The dosage of the composition of the present invention can be adjusted depending on the body weight, age, sex, health condition, diet, administration time, administration method, excretion rate and severity of disease of the patient, Those skilled in the art will appreciate that the present invention can be used within various ranges.
The functional food containing the composition according to the present invention can be used for various food products such as chewing gum, caramel product, candy, ice cream, confectionery, etc., soft drinks, mineral water, beverage products such as alcoholic drinks, vitamins and minerals It may be a healthy functional food.
The composition of the present invention can be added directly or together with other food or food ingredients, and can be suitably used according to conventional methods. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (prevention, health or hygiene). In general, the composition of the present invention is added in an amount of not more than 15% by weight, preferably not more than 10% by weight based on the raw material, in the production of food or beverage. However, in the case of long-term consumption intended for health or hygiene purposes or for health control purposes, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range.
The functional food comprising the composition according to the present invention may contain various flavors or natural carbohydrates as an additional ingredient. The above-mentioned natural carbohydrates are sugar saccharides such as monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like.
The ratio of the natural carbohydrate is preferably selected in the range of 0.01 to 0.04 part by weight, preferably about 0.02 to 0.03 part by weight per 100 parts by weight of the health food of the present invention.
In addition to the above, the functional food containing the composition of the present invention may be used in various foods such as various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickening agents, Preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. In addition, the functional food comprising the composition according to the present invention may contain flesh for the production of natural fruit juice, fruit juice drink and vegetable drink. These components may be used independently or in combination. The proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health food of the present invention.
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory and are intended to be illustrative of the present invention and the scope of the invention as defined by the appended claims. It will be obvious that such variations and modifications are intended to fall within the scope of the appended claims.
Example 1
The main ingredient is tocopherol (vitamin E) 10mg (purity 95% or more), zeaxanthin 2mg (extract containing more than 20%), lutein 10mg (extract containing more than 20%) and betasitosterol And 100 mg of soybean lecithin were mixed and 500 mg / capsule was prepared according to a conventional method to prepare capsules.
Example 2
As a main ingredient of bilberry extract, 10 mg of lutein and 2 mg of zeaxanthin, 100 mg of vitamin C and 7 mg of beta-sitosterol (95% or more), 381 mg of xylitol as an adjuvant and 2000 mg of ethanol were added to form granules, Dried at 60 DEG C and tableted with a tablet machine using a tablet machine.
Example 3
471 mg of xylitol was mixed with a mixture of 10 mg of lutein (extract containing at least 20%), 2 mg of zeaxanthin (extract containing at least 20%), 7 mg of beta-sitosterol (at least 95%) and 10 mg of tocopherol After granules were formed, they were dried at 60 DEG C and tableted with a tablet machine using a tablet machine.
Example 4
100 mg of vitamin C, 15 mg of tocopherol (vitamin E), 100 mg of soybean lecithin, and the remaining amount of olive oil (100 mg) is added to a mixture of 20 mg of lutein (extract containing 20% or more), 2 mg of zeaxanthin (extract containing more than 20%) and 7 mg of beta-sitosterol Were mixed, and 500 mg / capsule was prepared according to a conventional method to prepare capsules.
Claims (5)
50 parts by weight to 3,000 parts by weight of lutein; And
20 to 2,000 parts by weight of beta-sitosterol.
Wherein the composition further comprises one or more of 100 parts by weight to 40,000 parts by weight of vitamin C and 50 parts by weight to 3,000 parts by weight of vitamin E based on 100 parts by weight of zeaxanthin.
Soybean oil, soybean oil, soybean lecithin, xylitol, and olive oil.
Wherein the aging disease is one or more of gum deterioration and visual loss.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140121034A KR20160031247A (en) | 2014-09-12 | 2014-09-12 | Composition for improving senile disorder and functional foods comprising same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140121034A KR20160031247A (en) | 2014-09-12 | 2014-09-12 | Composition for improving senile disorder and functional foods comprising same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160031247A true KR20160031247A (en) | 2016-03-22 |
Family
ID=55644730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020140121034A KR20160031247A (en) | 2014-09-12 | 2014-09-12 | Composition for improving senile disorder and functional foods comprising same |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20160031247A (en) |
-
2014
- 2014-09-12 KR KR1020140121034A patent/KR20160031247A/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102070479B1 (en) | Prophylactic/therapeutic agent for dry eye | |
| JP7008909B2 (en) | Compositions containing cannabidiol or cannabis extract and caffeine and their applications | |
| WO2006035900A1 (en) | Coenzyme q10-containing emulsified composition | |
| JPWO2007037438A1 (en) | Metabolic syndrome improvement / prevention composition | |
| JP2013241354A (en) | Phosphodiesterase 2 inhibitor | |
| US10201578B2 (en) | Pharmaceutical composition or health food comprising Lonicera caerulea var. edulis fruit extracts as active ingredients for preventing or improving ischemic cerebrovascular diseases | |
| KR101426356B1 (en) | Composition for preventing or treating retinal disease containing extracts of persimmon | |
| US9527879B2 (en) | Aster glehni extracts, fractions or compounds isolated therefrom for the treatment or prevention of hyperuricemia or gout | |
| JP2012051821A (en) | Agent for preventing and ameliorating visual function | |
| JP5893438B2 (en) | Retinopathy preventive or ameliorating agent | |
| JP2007230881A (en) | Anti-fatigue composition | |
| KR20150001109A (en) | A composition for preventing or treating dementia through multi-target control | |
| KR20160031247A (en) | Composition for improving senile disorder and functional foods comprising same | |
| JP2005089374A (en) | Food and drink having function for preventing increase in blood glucose level | |
| US20080026086A1 (en) | Synergistic Neuroprotective, Combinations Of Flavanols, Hydroxystilbenes, Flavanones, Flavones, Flavonols, Proanthocyanidins And Anthocyanidins | |
| JP2009126814A (en) | Preventing or improving agent of hyperuricemia | |
| KR101806220B1 (en) | Antioxidant or anti-aging composition comprising lettuce flower extract or its fraction | |
| JP2005022994A (en) | Hypoglycemic composition | |
| JP2019001763A (en) | Blood cholesterol rise inhibitory composition | |
| CN103228602B (en) | Biphenol compound or its pharmacologically acceptable salt, for the preparation of the method for described biphenol compound or its pharmacologically acceptable salt, and for prevent or treat diabetic complication comprise its pharmaceutical composition as activeconstituents | |
| KR20170023055A (en) | Composition for prevention or treatment of retinal diseases comprising small black soybean extract | |
| JP2022050660A (en) | Blood cholesterol rise inhibitory composition | |
| KR20170005873A (en) | Oral composition for improving systemic symptoms including sensitivity to cold | |
| KR20210155350A (en) | Composition for improving uterine leiomyoma comprising green tea extract and vitamin d3 | |
| KR101185106B1 (en) | Composition for descending intraocular pressure containing extractions of the lindera genus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |